Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease
MWN-AI** Summary
Anavex Life Sciences Corp. presented promising new data on its investigational Alzheimer's treatment, oral blarcamesine, during the AD/PD™ 2026 Conference. The data, reported by Prof. Dr. Timo Grimmer, revealed a significant correlation between treatment effects and brain volume preservation in early-stage Alzheimer’s patients. Notably, long-term findings indicated that patients treated with blarcamesine saved an impressive 77.4 weeks (or 17.8 months) in disease progression compared to the control group over 144 weeks of treatment.
The Phase IIb/III trial, ANAVEX®2-73-AD-004, alongside its open-label extension study, provided critical insights into the medication's safety and efficacy. Prof. Grimmer highlighted blarcamesine’s ease of administration, low side effects, and substantial clinical benefits, particularly for patients identified through genetic markers in the ABCLEAR32 population, which demonstrated amplified response rates.
In addition to cognitive improvements measured by the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13), researchers observed a stable relationship between brain volume preservation and functional outcomes across primary and secondary clinical measures, such as the Activities of Daily Living scale (ADCS-ADL) and the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB). Notably, the correlation for cognitive outcomes in the ABCLEAR32 group increased significantly, reinforcing blarcamesine’s potential as a targeted precision medicine for Alzheimer’s disease.
Christopher U. Missling, CEO of Anavex, emphasized the drug’s coherent effects in neuroprotection and its role as a promising disease-modifying treatment. This compelling data underscores Anavex's commitment to advancing therapeutic options for Alzheimer’s patients, leveraging genomic insights to maximize treatment efficacy. The company looks forward to further clinical developments that may improve outcomes for individuals affected by neurodegenerative disorders.
MWN-AI** Analysis
Anavex Life Sciences Corp. (NASDAQ: AVXL) has recently generated significant interest in the biotechnology sector with the presentation of new data on its promising Alzheimer's treatment, blarcamesine (ANAVEX®2-73), at the AD/PD™ 2026 Conference. The reported findings underscore a consistent correlation between the neuroprotective effects of blarcamesine and the preservation of brain volume among early Alzheimer's patients, positioning it as a potentially game-changing candidate in Alzheimer's treatment.
The data reveal that participants receiving oral blarcamesine experienced an impressive 77.4 weeks (17.8 months) of preserved cognitive function compared to the control group after a treatment period concluding at 144 weeks (33.1 months). This metric not only highlights the drug's efficacy but also its practicality for both patients and caregivers, as an oral administration model significantly enhances compliance and quality of life.
One of the key takeaways from the study is the precision medicine approach, where blarcamesine appears particularly effective in patients with specific genetic markers (the ABCLEAR32 population). The marked improvement in cognitive assessments and daily living activities corroborates the potential of blarcamesine to modify the disease course.
Investors should take note of Anavex's robust clinical pipeline and the anticipated progression towards pivotal trials based on these encouraging outcomes. The correlation between structural brain preservation and clinical improvement further strengthens the company's position in the competitive landscape of neurodegenerative disease therapies.
Given the considerable healthcare market for Alzheimer's solutions and the ongoing support from the scientific community, Anavex Life Sciences holds substantial upside potential. For investors, now might be an opportune time to evaluate entering or expanding a position in AVXL, keeping in mind the associated risks inherent in clinical-stage biopharmaceutical companies. As developments unfold, monitoring future clinical trials and regulatory updates will be crucial for strategic investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
New data show brain-volume preservation correlates with patient outcomes
Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatment
Oral presentation at the AD/PD™ 2026 Conference Symposium: ‘Advances in AD treatment’ highlights the convenience of oral blarcamesine for both patients and families
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new data of blarcamesine was presented at the AD/PD™ 2026 Conference by Prof. Dr. Timo Grimmer, MD, and collaborators, titled, Advancing Alzheimer’s Disease Care: Convenience for both Patients and Families with Oral Blarcamesine with Long-term Time Saved, drawing from the ANAVEX®2-73-AD-004 (NCT03790709) Phase IIb/III clinical program and its long-term open-label extension, ANAVEX®2-73-AD-EP-004 (NCT04314934).
“The patient-friendly oral administration, the manageable side effects, and the clinical efficacy—particularly in the genetically defined ABCLEAR32 population—make blarcamesine, in conjunction with the associated biomarker signal, a promising drug candidate for patients with early-stage Alzheimer’s disease,” said Prof. Dr Timo Grimmer, MD, member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX®2-73-AD-004 study. “Alzheimer’s disease is a devastating chronic disease that affects millions worldwide. We believe, these new results will contribute to the growing body of scientific data demonstrating the long-term beneficial effect of blarcamesine in early Alzheimer’s disease.”
Data from the ANAVEX®2-73-AD-004 study also show that patients with wild-type (WT) SIGMAR1 and COL24A1 genes, the ABCLEAR32 population, may experience substantially greater clinical and structural benefit from blarcamesine. This reinforces Anavex’s precision medicine strategy, leveraging genomic and biomarker-based indicators to optimize therapeutic efficacy.3
A dedicated analysis of MRI biomarkers demonstrated a highly consistent correlation between slowing of atrophy and improvements across primary and secondary clinical endpoints, including:
- ADAS-Cog13 (cognition)
- ADCS-ADL (activities of daily living)
- CDR-SB (global clinical cognitive and functional outcome)
In the genetically defined ABCLEAR32 precision medicine population, the correlation (R²) strength improved markedly, with R² increasing by 78% for ADAS-Cog13 (from R²=0.23 to R²=0.41)—firmly within the “very suggestive” range for clinical relevance.
“These results indicate that blarcamesine’s clinical effects are biologically coherent with MRI-based measures of neuroprotection,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The consistent relation between structural preservation of brain volume and functional outcomes further drives our dedication to developing a novel disease-modifying Alzheimer’s treatment with our oral blarcamesine.”
The AD/PD™ 2026 Conference presentation is available on the Investors section of the Company’s website at www.anavex.com.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
About AD/PD™ 2026 Conference
The AD/PD™ Alzheimer’s Disease and Parkinson’s Disease Conference will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer’s, Parkinson’s, and other related neurological disorders.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, blarcamesine (ANAVEX®2-73), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Blarcamesine is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. Blarcamesine also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop blarcamesine for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
________________________________
1 ADNI = Alzheimer’s Disease Neuroimaging Initiative. https://adni.loni.usc.edu
2 ABCLEAR3 = Alzheimer’s Blarcamesine Cognition Efficacy and Resilience gene variants non-carrier population (SIGMAR1 wild type [WT]/COL24A1 wild type [WT])
3 https://www.medrxiv.org/content/10.1101/2025.09.27.25336656v1.full.pdf
FAQ**
How does the data presented by Anavex Life Sciences Corp. (AVXL) on blarcamesine's brain-volume preservation correlate with patient outcomes in early-stage Alzheimer’s disease?
What mechanisms does Anavex Life Sciences Corp. (AVXL) believe contribute to the long-term clinical benefits observed with oral blarcamesine over the 144-week treatment period?
Can you elaborate on the significance of the ABCLEARpopulation identified by Anavex Life Sciences Corp. (AVXL) in enhancing the drug's precision medicine approach for Alzheimer's treatment?
What implications do the findings from Anavex Life Sciences Corp. (AVXL) regarding MRI biomarker correlations have on the future development of disease-modifying therapies for neurodegenerative disorders?
**MWN-AI FAQ is based on asking OpenAI questions about Anavex Life Sciences Corp. (NASDAQ: AVXL).
NASDAQ: AVXL
AVXL Trading
-0.17% G/L:
$2.99 Last:
1,166,347 Volume:
$3.04 Open:
